查看购物车
  • Traditional Chinese
  • English
2031年亚太细胞和基因治疗市场预测—区域分析—按类型、服务、规模、服务提供者和最终用户
市场调查报告书
商品编码
1764841

2031年亚太细胞和基因治疗市场预测—区域分析—按类型、服务、规模、服务提供者和最终用户

Asia Pacific Cell and Gene Therapy Market Forecast to 2031 - Regional Analysis - by Type, Services, Scale, Service Providers, and End User
出版日期: | 出版商: The Insight Partners | 英文 161 Pages | 订单完成后即时交付

价格

2023 年亚太细胞和基因治疗市值为 10.2437 亿美元，预计到 2031 年将达到 80.1275 亿美元；预计 2023 年至 2031 年的复合年增长率为 29.3%。

公司策略措施推动亚太细胞和基因治疗市场

许多参与细胞和基因治疗产品生产的公司专注于合作、扩张、协议、伙伴关係、新产品发布和其他策略发展。这些策略倡议有助于他们提高销售额、扩大地理覆盖范围并增强服务庞大客户群的能力。细胞和基因治疗市场的一些重要发展包括：2023年9月，安捷伦科技公司与新加坡先进细胞治疗与研究中心（ACTRIS）签署了一份谅解备忘录（MOU）。该协议旨在未来三年推动细胞和基因治疗领域的进步。 2023年3月，Cellevolve Bio与西雅图儿童治疗公司合作，开发并商业化用于治疗儿童癌症的新型多重嵌合抗原受体（CAR）药物。透过此次合作，两家公司将专注于BrainChild研究计画——一套由五种多重CAR组成的方案——用于治疗儿童中枢神经系统（CNS）恶性肿瘤。他们计划利用西雅图儿童治疗工厂的设施进行新型CAR的早期临床GMP研究。 2023年3月，Twist Bioscience Corporation与Kriya Therapeutics, Inc.达成一项抗体发现协议，旨在开发利用腺相关病毒(AAV)基因疗法递送的抗体，用于肿瘤治疗应用。此外，两家公司还计划将Twist的抗体库与Kriya专有的载体工程平台结合，以发现针对特定标靶的新型抗体，并利用Kriya的基因治疗技术进行递送。 2023年1月，富士软片株式会社同意收购Atara Biotherapeutics, Inc.旗下的一家细胞疗法生产厂。该工厂将进行扩建，以灵活地生产临床和商业细胞疗法，例如同种异体T细胞和CAR-T免疫疗法。透过合作和伙伴关係开展新业务以保持市场竞争力，有助于加速开发新的细胞和基因疗法生产服务平台。因此，预计主要参与者的这些策略倡议将在预测期内为亚太细胞和基因疗法市场创造巨大的成长机会。

亚太细胞和基因治疗市场概览

中国在基因和细胞治疗领域正在取得进展。中国拥有庞大的患者群体，这对于开发此类疗法的公司来说是一个极具吸引力的市场。中国多家公司正在研发针对癌症和遗传性疾病等疾病的创新疗法，并在基因治疗研发方面投入了大量资金。中国于2003年成为首个批准基因治疗的国家；自此之后，全球细胞和基因治疗发展迅速，其治疗潜力也大幅提升。中华人民共和国政府已实施多项监管改革，以促进细胞和基因治疗的规范发展。根据2021年发表在《自然》杂誌上的一项研究，全球超过50%的细胞治疗试验在中国进行。中国目前有近400项CAR-T试验正在进行中，主要针对血液学、肿瘤学和实体肿瘤。随着復星凯特的Yescarta和药明巨诺的Relma-cel于2021年获得国家药品监督管理局（NMPA）的批准，中国的细胞治疗正迈入一个新时代。 2023年10月，科济生物和信达生物分别获得国家药品监督管理局（NMPA）批准，获得针对B细胞成熟抗原的CAR-T疗法新药上市许可。预计这些疗法将很快获得批准并实现商业化。

亚太细胞及基因治疗市场收入及预测（2031年）（百万美元）

亚太细胞和基因治疗市场细分

亚太细胞和基因治疗市场按类型、服务、规模、最终用户和国家分类。

根据类型，亚太细胞和基因治疗市场分为细胞治疗和基因治疗。 2023年，细胞治疗占据了更大的市场。此外，细胞治疗细分市场又细分为同种异体载体、自体载体和病毒载体。基因治疗细分市场又细分为非病毒载体和病毒载体。

就服务而言，亚太细胞和基因治疗市场分为製程开发、cGMP製造、监管服务和生物测定服务。製程开发领域在2023年占据了最大的市场。

按规模划分，亚太地区细胞和基因治疗市场分为商业化前/研发生产和商业化规模生产。 2023年，商业化前/研发生产领域占据了更大的市场份额。

根据最终用户，亚太细胞和基因治疗市场细分为合约研究组织、製药和生物製药公司以及学术和研究机构。製药和生物製药公司在2023年占据了最大的市场。

按国家/地区划分，亚太细胞和基因治疗市场分为中国、日本、印度、澳洲、韩国和亚太其他地区。 2023年，中国占据了亚太细胞和基因治疗市场的主导地位。

Catalent Inc、Charles River Laboratories International Inc、F. Hoffmann-La Roche Ltd、FUJIFILM Holdings Corp、Lonza Group AG、乐天公司、默克集团、Takara Bio Inc、赛默飞世尔科技公司和药明康德股份有限公司是亚太细胞和基因治疗市场的一些领先公司。

目录

第一章：简介

第二章：执行摘要

  • 关键见解

第三章：研究方法

  • 二次研究
  • 初步研究
    • 假设表述：
    • 宏观经济因素分析：
    • 显影基数：
    • 数据三角测量：
    • 国家级资料：

第四章：亚太地区细胞与基因治疗市场格局

  • 概述
  • PEST分析

第五章：亚太细胞与基因治疗市场－关键市场动态

  • 细胞与基因治疗市场—关键市场动态
  • 市场驱动因素
    • 细胞和基因疗法获批数量的增加
    • 外包细胞与基因治疗製造迅速普及
  • 市场限制
    • 细胞和基因治疗製造成本高昂
  • 市场机会
    • 企业的策略倡议
  • 未来趋势
    • 细胞和基因治疗製造服务的自动化
  • 驱动因素和限制因素的影响：

第六章：细胞与基因治疗市场-亚太市场分析

  • 亚太细胞和基因治疗市场概览
  • 2021-2031年亚太细胞及基因治疗市场收入
  • 细胞和基因治疗市场预测分析

第七章：亚太地区细胞与基因治疗市场分析 - 按类型

  • 细胞疗法
  • 基因治疗

第八章：亚太地区细胞和基因治疗市场分析 - 按服务

  • 製程开发
  • cGMP 製造
  • 监管服务
  • 生物测定服务

第九章：亚太地区细胞与基因治疗市场分析－依规模

  • 商业化前/研发製造
  • 商业规模生产

第十章：亚太地区细胞与基因治疗市场分析—服务提供者

  • 合约製造与生产组织
  • 首席行销长

第 11 章：亚太细胞和基因治疗市场分析 - 按最终用户

  • 合约研究组织
  • 製药和生物製药公司
  • 学术和研究机构

第 12 章：亚太细胞与基因治疗市场 - 国家分析

  • 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太其他地区

第十三章：产业格局

  • 概述
  • 细胞和基因治疗市场的成长策略
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第 14 章：公司简介

  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Charles River Laboratories International Inc
  • Lonza Group AG
  • WuXi AppTec Co Ltd
  • Takara Bio Inc
  • FUJIFILM Holdings Corp
  • F. Hoffmann-La Roche Ltd
  • Catalent Inc
  • Lotte Corp

第 15 章：附录

Product Code: BMIRE00031472

The Asia Pacific cell and gene therapy market was valued at US$ 1,024.37 million in 2023 and is projected to reach US$ 8,012.75 million by 2031; it is estimated to record a CAGR of 29.3% from 2023 to 2031.

Strategic Initiatives by Companies Drive Asia Pacific Cell and Gene Therapy Market

Many companies involved in manufacturing cell and gene therapy products focus on collaborations, expansions, agreements, partnerships, new product launches, and other strategic developments. These strategic initiatives help them improve sales, expand geographic reach, and enhance capacities to cater to a large customer base. A few of the significant developments in the cell and gene therapy market are; In September 2023, Agilent Technologies Inc. signed a Memorandum of Understanding (MOU) with the Advanced Cell Therapy and Research Institute, Singapore (ACTRIS). This agreement aims to improve cell and gene therapy advancements over the next three years. In March 2023, Cellevolve Bio partnered with Seattle Children's Therapeutics to develop and commercialize new multiplex CARs for pediatric cancers. With this collaboration, the companies will focus on the BrainChild research program-a suite of five multiplex CARs-to treat pediatric central nervous system (CNS) malignancies. They aim to leverage the Seattle Children's Cure Factory facility to conduct early clinical GMP research on new CARs. In March 2023, Twist Bioscience Corporation and Kriya Therapeutics, Inc. entered an antibody discovery agreement for antibodies delivered using adeno-associated viral (AAV) gene therapy in therapeutic oncology applications. Also, the companies aim to combine Twist's antibody libraries with Kriya's proprietary vector engineering platform to discover novel antibodies against specific targets of interest to be delivered with Kriya's gene therapy technology. In January 2023, FUJIFILM Corporation agreed to acquire a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. The facility will witness expansion with the flexibility to produce clinical as well as commercial cell therapies, such as allogeneic T-cell and CAR T immunotherapies. The initiation of new businesses to remain competitive in the market through collaborations and partnerships can help accelerate the development of new platforms for cell and gene therapy manufacturing services. Thus, these strategic initiatives by key players are anticipated to create substantial growth opportunities in the Asia Pacific cell and gene therapy market during the forecast period.

Asia Pacific Cell and Gene Therapy Market Overview

China is making progress in gene and cell therapy. The country has a large patient population making it an attractive market for companies developing these treatments. Several companies are working on innovative therapies for diseases such as cancer and genetic disorders in China, and the country has invested heavily in gene therapy research and development. China was the first country to approve gene therapy in 2003; since then, cell and gene therapy developments have advanced rapidly worldwide, and their therapeutic potential has soared. The government of the People's Republic of China has conducted several regulatory reforms to promote the normative development of cell and gene therapies. According to a study published in Nature in 2021, China is home to more than 50% of all cell therapy trials worldwide. China has nearly 400 ongoing CAR-T trials centered on hematology, oncology, and solid tumors. Cell therapy in China is entering a new era with the approval of Fosun Kite's Yescarta and JW Therapeutics' Relma-cel in 2021 from the National Medical Products Administration (NMPA). In October 2023, CARsgen and IASO Biotherapeutics/Innovent were approved by the NMPA for new drug approvals targeting B-cell maturation antigens in CAR-T. These therapies are expected to be approved and commercialized soon.

Asia Pacific Cell and Gene Therapy Market Revenue and Forecast to 2031 (US$ Million)

Asia Pacific Cell and Gene Therapy Market Segmentation

The Asia Pacific cell and gene therapy market is categorized into type, services, scale, end user, and country.

Based on type, the Asia Pacific cell and gene therapy market is bifurcated into cell therapy and gene therapy. The cell therapy segment held a larger market share in 2023. Furthermore, the cell therapy segment is sub segmented into allogeneic, autologous, viral vectors. Additionally, the gene therapy segment is divided into non-viral vectors and viral vectors.

In terms of services, the Asia Pacific cell and gene therapy market is categorized process development, cGMP manufacturing, regulatory services, and bioassay services. The process development segment held the largest market share in 2023.

By scale, the Asia Pacific cell and gene therapy market is bifurcated into pre-commercial/R&D manufacturing and commercial scale manufacturing. The pre-commercial/R&D manufacturing segment held a larger market share in 2023.

Based on end user, the Asia Pacific cell and gene therapy market is segmented into contract research organizations, pharmaceutical and biopharmaceutical companies, and academic and research institutes. The pharmaceutical and biopharmaceutical companies segment held the largest market share in 2023.

By country, the Asia Pacific cell and gene therapy market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific cell and gene therapy market share in 2023.

Catalent Inc, Charles River Laboratories International Inc, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings Corp, Lonza Group AG, Lotte Corp, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc., and WuXi AppTec Co Ltd are some of the leading companies operating in the Asia Pacific cell and gene therapy market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Asia Pacific Cell and Gene Therapy Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Asia Pacific Cell and Gene Therapy Market - Key Market Dynamics

  • 5.1 Cell and Gene Therapy Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Increase in Number of Approval of Cell and Gene Therapies
    • 5.2.2 Rapid Popularity of Outsourcing Cell and Gene Therapy Manufacturing
  • 5.3 Market Restraints
    • 5.3.1 High Cost of Cell and Gene Therapy Manufacturing
  • 5.4 Market Opportunities
    • 5.4.1 Strategic Initiatives by Companies
  • 5.5 Future Trends
    • 5.5.1 Automation of Cell and Gene Therapy Manufacturing Services
  • 5.6 Impact of Drivers and Restraints:

6. Cell and Gene Therapy Market -Asia Pacific Market Analysis

  • 6.1 Asia Pacific Cell and Gene Therapy Market Overview
  • 6.2 Asia Pacific Cell and Gene Therapy Market Revenue (US$ Million), 2021-2031
  • 6.3 Cell and Gene Therapy Market Forecast Analysis

7. Asia Pacific Cell and Gene Therapy Market Analysis - by Type

  • 7.1 Cell Therapy
    • 7.1.1 Overview
    • 7.1.2 Cell Therapy: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Gene Therapy
    • 7.2.1 Overview
    • 7.2.2 Gene Therapy: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

8. Asia Pacific Cell and Gene Therapy Market Analysis - by Services

  • 8.1 Process Development
    • 8.1.1 Overview
    • 8.1.2 Process Development: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 cGMP Manufacturing
    • 8.2.1 Overview
    • 8.2.2 cGMP Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Regulatory Services
    • 8.3.1 Overview
    • 8.3.2 Regulatory Services: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Bioassay Services
    • 8.4.1 Overview
    • 8.4.2 Bioassay Services: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

9. Asia Pacific Cell and Gene Therapy Market Analysis - by Scale

  • 9.1 Pre-Commercial/R&D Manufacturing
    • 9.1.1 Overview
    • 9.1.2 Pre-Commercial/R&D Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Commercial Scale Manufacturing
    • 9.2.1 Overview
    • 9.2.2 Commercial Scale Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

10. Asia Pacific Cell and Gene Therapy Market Analysis - by Service Providers

  • 10.1 CDMOs
    • 10.1.1 Overview
    • 10.1.2 CDMOs: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2 CMOs
    • 10.2.1 Overview
    • 10.2.2 CMOs: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

11. Asia Pacific Cell and Gene Therapy Market Analysis - by End User

  • 11.1 Contract Research Organizations
    • 11.1.1 Overview
    • 11.1.2 Contract Research Organizations: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • 11.2 Pharmaceutical and Biopharmaceutical Companies
    • 11.2.1 Overview
    • 11.2.2 Pharmaceutical and Biopharmaceutical Companies: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • 11.3 Academic and Research Institutes
    • 11.3.1 Overview
    • 11.3.2 Academic and Research Institutes: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)

12. Asia Pacific Cell and Gene Therapy Market - Country Analysis

  • 12.1 Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
    • 12.1.1 Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast Analysis - by Country
      • 12.1.1.1 Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast Analysis - by Country
      • 12.1.1.2 China: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
        • 12.1.1.2.1 China: Cell and Gene Therapy Market Breakdown, by Type
          • 12.1.1.2.1.1 China: Cell and Gene Therapy Market Breakdown, by Cell Therapy
          • 12.1.1.2.1.2 China: Cell and Gene Therapy Market Breakdown, by Gene Therapy
        • 12.1.1.2.2 China: Cell and Gene Therapy Market Breakdown, by Services
        • 12.1.1.2.3 China: Cell and Gene Therapy Market Breakdown, by Scale
        • 12.1.1.2.4 China: Cell and Gene Therapy Market Breakdown, by Service Providers
        • 12.1.1.2.5 China: Cell and Gene Therapy Market Breakdown, by End User
      • 12.1.1.3 Japan: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
        • 12.1.1.3.1 Japan: Cell and Gene Therapy Market Breakdown, by Type
          • 12.1.1.3.1.1 Japan: Cell and Gene Therapy Market Breakdown, by Cell Therapy
          • 12.1.1.3.1.2 Japan: Cell and Gene Therapy Market Breakdown, by Gene Therapy
        • 12.1.1.3.2 Japan: Cell and Gene Therapy Market Breakdown, by Services
        • 12.1.1.3.3 Japan: Cell and Gene Therapy Market Breakdown, by Scale
        • 12.1.1.3.4 Japan: Cell and Gene Therapy Market Breakdown, by Service Providers
        • 12.1.1.3.5 Japan: Cell and Gene Therapy Market Breakdown, by End User
      • 12.1.1.4 India: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
        • 12.1.1.4.1 India: Cell and Gene Therapy Market Breakdown, by Type
          • 12.1.1.4.1.1 India: Cell and Gene Therapy Market Breakdown, by Cell Therapy
          • 12.1.1.4.1.2 India: Cell and Gene Therapy Market Breakdown, by Gene Therapy
        • 12.1.1.4.2 India: Cell and Gene Therapy Market Breakdown, by Services
        • 12.1.1.4.3 India: Cell and Gene Therapy Market Breakdown, by Scale
        • 12.1.1.4.4 India: Cell and Gene Therapy Market Breakdown, by Service Providers
        • 12.1.1.4.5 India: Cell and Gene Therapy Market Breakdown, by End User
      • 12.1.1.5 Australia: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
        • 12.1.1.5.1 Australia: Cell and Gene Therapy Market Breakdown, by Type
          • 12.1.1.5.1.1 Australia: Cell and Gene Therapy Market Breakdown, by Cell Therapy
          • 12.1.1.5.1.2 Australia: Cell and Gene Therapy Market Breakdown, by Gene Therapy
        • 12.1.1.5.2 Australia: Cell and Gene Therapy Market Breakdown, by Services
        • 12.1.1.5.3 Australia: Cell and Gene Therapy Market Breakdown, by Scale
        • 12.1.1.5.4 Australia: Cell and Gene Therapy Market Breakdown, by Service Providers
        • 12.1.1.5.5 Australia: Cell and Gene Therapy Market Breakdown, by End User
      • 12.1.1.6 South Korea: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
        • 12.1.1.6.1 South Korea: Cell and Gene Therapy Market Breakdown, by Type
          • 12.1.1.6.1.1 South Korea: Cell and Gene Therapy Market Breakdown, by Cell Therapy
          • 12.1.1.6.1.2 South Korea: Cell and Gene Therapy Market Breakdown, by Gene Therapy
        • 12.1.1.6.2 South Korea: Cell and Gene Therapy Market Breakdown, by Services
        • 12.1.1.6.3 South Korea: Cell and Gene Therapy Market Breakdown, by Scale
        • 12.1.1.6.4 South Korea: Cell and Gene Therapy Market Breakdown, by Service Providers
        • 12.1.1.6.5 South Korea: Cell and Gene Therapy Market Breakdown, by End User
      • 12.1.1.7 Rest of Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
        • 12.1.1.7.1 Rest of Asia Pacific: Cell and Gene Therapy Market Breakdown, by Type
          • 12.1.1.7.1.1 Rest of Asia Pacific: Cell and Gene Therapy Market Breakdown, by Cell Therapy
          • 12.1.1.7.1.2 Rest of Asia Pacific: Cell and Gene Therapy Market Breakdown, by Gene Therapy
        • 12.1.1.7.2 Rest of Asia Pacific: Cell and Gene Therapy Market Breakdown, by Services
        • 12.1.1.7.3 Rest of Asia Pacific: Cell and Gene Therapy Market Breakdown, by Scale
        • 12.1.1.7.4 Rest of Asia Pacific: Cell and Gene Therapy Market Breakdown, by Service Providers
        • 12.1.1.7.5 Rest of Asia Pacific: Cell and Gene Therapy Market Breakdown, by End User

13. Industry Landscape

  • 13.1 Overview
  • 13.2 Growth Strategies in Cell and Gene Therapy Market
  • 13.3 Organic Growth Strategies
    • 13.3.1 Overview
  • 13.4 Inorganic Growth Strategies
    • 13.4.1 Overview

14. Company Profiles

  • 14.1 Thermo Fisher Scientific Inc.
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Merck KGaA
    • 14.2.1 Key Facts
    • 14.2.2 Business Description
    • 14.2.3 Products and Services
    • 14.2.4 Financial Overview
    • 14.2.5 SWOT Analysis
    • 14.2.6 Key Developments
  • 14.3 Charles River Laboratories International Inc
    • 14.3.1 Key Facts
    • 14.3.2 Business Description
    • 14.3.3 Products and Services
    • 14.3.4 Financial Overview
    • 14.3.5 SWOT Analysis
    • 14.3.6 Key Developments
  • 14.4 Lonza Group AG
    • 14.4.1 Key Facts
    • 14.4.2 Business Description
    • 14.4.3 Products and Services
    • 14.4.4 Financial Overview
    • 14.4.5 SWOT Analysis
    • 14.4.6 Key Developments
  • 14.5 WuXi AppTec Co Ltd
    • 14.5.1 Key Facts
    • 14.5.2 Business Description
    • 14.5.3 Products and Services
    • 14.5.4 Financial Overview
    • 14.5.5 SWOT Analysis
    • 14.5.6 Key Developments
  • 14.6 Takara Bio Inc
    • 14.6.1 Key Facts
    • 14.6.2 Business Description
    • 14.6.3 Products and Services
    • 14.6.4 Financial Overview
    • 14.6.5 SWOT Analysis
    • 14.6.6 Key Developments
  • 14.7 FUJIFILM Holdings Corp
    • 14.7.1 Key Facts
    • 14.7.2 Business Description
    • 14.7.3 Products and Services
    • 14.7.4 Financial Overview
    • 14.7.5 SWOT Analysis
    • 14.7.6 Key Developments
  • 14.8 F. Hoffmann-La Roche Ltd
    • 14.8.1 Key Facts
    • 14.8.2 Business Description
    • 14.8.3 Products and Services
    • 14.8.4 Financial Overview
    • 14.8.5 SWOT Analysis
    • 14.8.6 Key Developments
  • 14.9 Catalent Inc
    • 14.9.1 Key Facts
    • 14.9.2 Business Description
    • 14.9.3 Products and Services
    • 14.9.4 Financial Overview
    • 14.9.5 SWOT Analysis
    • 14.9.6 Key Developments
  • 14.10 Lotte Corp
    • 14.10.1 Key Facts
    • 14.10.2 Business Description
    • 14.10.3 Products and Services
    • 14.10.4 Financial Overview
    • 14.10.5 SWOT Analysis
    • 14.10.6 Key Developments

15. Appendix

  • 15.1 About The Insight Partners
  • 15.2 Glossary of Terms

List Of Tables

  • Table 1. Cell and Gene Therapy Market Segmentation
  • Table 2. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Table 3. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million) - by Type
  • Table 4. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million) - by Cell Therapy
  • Table 5. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million) - by Gene Therapy
  • Table 6. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million) - by Services
  • Table 7. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million) - by Scale
  • Table 8. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million) - by Service Providers
  • Table 9. Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 10. Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Country
  • Table 11. China: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 12. China: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Cell Therapy
  • Table 13. China: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Gene Therapy
  • Table 14. China: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Services
  • Table 15. China: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Scale
  • Table 16. China: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Service Providers
  • Table 17. China: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 18. Japan: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 19. Japan: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Cell Therapy
  • Table 20. Japan: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Gene Therapy
  • Table 21. Japan: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Services
  • Table 22. Japan: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Scale
  • Table 23. Japan: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Service Providers
  • Table 24. Japan: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 25. India: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 26. India: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Cell Therapy
  • Table 27. India: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Gene Therapy
  • Table 28. India: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Services
  • Table 29. India: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Scale
  • Table 30. India: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Service Providers
  • Table 31. India: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 32. Australia: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 33. Australia: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Cell Therapy
  • Table 34. Australia: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Gene Therapy
  • Table 35. Australia: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Services
  • Table 36. Australia: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Scale
  • Table 37. Australia: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Service Providers
  • Table 38. Australia: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 39. South Korea: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 40. South Korea: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Cell Therapy
  • Table 41. South Korea: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Gene Therapy
  • Table 42. South Korea: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Services
  • Table 43. South Korea: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Scale
  • Table 44. South Korea: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Service Providers
  • Table 45. South Korea: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 46. Rest of Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 47. Rest of Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Cell Therapy
  • Table 48. Rest of Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Gene Therapy
  • Table 49. Rest of Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Services
  • Table 50. Rest of Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Scale
  • Table 51. Rest of Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by Service Providers
  • Table 52. Rest of Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 53. Recent Organic Growth Strategies in Cell and Gene Therapy Market
  • Table 54. Recent Inorganic Growth Strategies in the Cell and Gene Therapy Market
  • Table 55. Glossary of Terms

List Of Figures

  • Figure 1. Cell and Gene Therapy Market Segmentation, by Country
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Cell and Gene Therapy Market Revenue (US$ Million), 2021-2031
  • Figure 5. Cell and Gene Therapy Market Share (%) - by Type (2023 and 2031)
  • Figure 6. Cell Therapy: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Gene Therapy: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Cell and Gene Therapy Market Share (%) - by Services (2023 and 2031)
  • Figure 9. Process Development: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. cGMP Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Regulatory Services: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Bioassay Services: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Cell and Gene Therapy Market Share (%) - by Scale (2023 and 2031)
  • Figure 14. Pre-Commercial/R&D Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Commercial Scale Manufacturing: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Cell and Gene Therapy Market Share (%) - by Service Providers (2023 and 2031)
  • Figure 17. CDMOs: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. CMOs: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Cell and Gene Therapy Market Share (%) - by End User (2023 and 2031)
  • Figure 20. Contract Research Organizations: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Pharmaceutical and Biopharmaceutical Companies: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Academic and Research Institutes: Cell and Gene Therapy Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. Asia Pacific Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 24. Asia Pacific Cell and Gene Therapy Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 25. China: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 26. Japan: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 27. India: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 28. Australia: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 29. South Korea: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 30. Rest of Asia Pacific: Cell and Gene Therapy Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 31. Growth Strategies in Cell and Gene Therapy Market